

1 Effects of semi-solidification of enteral nutrients on the pharmacokinetic behavior of  
2 orally administered carbamazepine in rats

3

4

5 Katsuhito Nagai<sup>1</sup>, Sachiko Omotani<sup>1</sup>, Masahito Shibano<sup>1</sup>, Akihide Kobayashi<sup>1</sup>, Akihiko  
6 Ito<sup>2</sup>, Ikumi Nishimura<sup>2</sup>, Yasutoshi Hatsuda<sup>1</sup>, Junji Mukai<sup>1</sup>, Hitomi Teramachi<sup>3</sup>, Michiaki  
7 Myotoku<sup>1</sup>

8

9

10 <sup>1</sup>Laboratory of Practical Pharmacy and Pharmaceutical Care, Faculty of Pharmacy,  
11 Osaka Ohtani University, 3-11-1 Nishikiori-kita, Tondabayashi, 584-0066, Japan

12 <sup>2</sup>National Hospital Organization Higashi-Ohmi General Medical Center, 255, Gochi-cho,  
13 Higashiomi, 527-8505, Japan

14 <sup>3</sup>Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifushi, 501-1196, Japan

15

16

17 Corresponding author – Michiaki Myotoku, Ph. D.

18 Tel : +81-721-24-9531

19 Fax: +81-721-24-9531

20 E-mail: myoutom@osaka-ohtani.ac.jp

21 Laboratory of Practical Pharmacy and Pharmaceutical Care, Faculty of Pharmacy,  
22 Osaka Ohtani University, 3-11-1 Nishikiori-kita, Tondabayashi, 584-0066, Japan

1 **ABSTRACT**

2 The use of semi-solid enteral nutrients plays an extremely important role in accurate  
3 nutrition management. In the present study, we compared the pharmacokinetic profile  
4 of orally administered carbamazepine (CBZ) in rats treated with liquid RACOL<sup>®</sup>,  
5 semi-solid RACOL<sup>®</sup>, and HINE E-gel<sup>®</sup>, which are enteral nutrients marketed in Japan.  
6 Since liquid and semi-solid formulations are both marketed in Japan for RACOL<sup>®</sup>,  
7 liquid RACOL<sup>®</sup> was orally administered to control rats. The serum concentration of  
8 CBZ at each sampling point was lower in the semi-solid RACOL<sup>®</sup>-treated group than in  
9 the liquid RACOL<sup>®</sup>-treated group. No significant differences were observed in the  
10 pharmacokinetic behavior of CBZ between the semi-solid RACOL<sup>®</sup>-treated and HINE  
11 E-gel<sup>®</sup>-treated groups. Regarding pharmacokinetic parameters, the impact of the area  
12 under the curve (AUC<sub>0→5h</sub>) was the liquid RACOL<sup>®</sup> group > the semi-solid RACOL<sup>®</sup>  
13 group ≈ the HINE E-gel<sup>®</sup> group. Therefore, we concluded that serum concentrations  
14 of CBZ were lower when concurrently treating with semi-solid enteral nutrients than  
15 when simultaneously processing liquid enteral nutrients.

16

17

18 **KEYWORDS**

19 Nutrition management; semi-solid enteral nutrient; carbamazepine; pharmacokinetics

20

21

22

1    **INTRODUCTION**

2       Adequate feeding with liquid enteral nutrients is essential for critically ill patients  
3    and helps to prevent malnutrition and its accompanying complications [1]. Despite its  
4    benefits, feeding with liquid enteral nutrients is occasionally accompanied by adverse  
5    effects, such as diarrhea and aspiration pneumonia [2,3]. Semi-solid enteral nutrients  
6    are considered to be useful for decreasing the adverse events associated with liquid  
7    enteral nutrients during feeding [4,5]. However, dietary fibers used for the  
8    semi-solidification of enteral nutrients have been shown to interact with clinical drugs  
9    [6]. We also previously demonstrated that the pharmacokinetic behavior of  
10   carbamazepine (CBZ), a tricyclic anticonvulsant, after its oral administration was  
11   affected by concurrent treatments with these fibers in rats [7,8]. Therefore, we  
12   hypothesized that a pharmacokinetic interaction may occur between CBZ and  
13   semi-solid enteral nutrients.

14       The aim of the present study was to investigate whether the pharmacokinetic profile  
15   of orally administered CBZ was altered in rats by concurrent treatments with semi-solid  
16   RACOL<sup>®</sup> and HINE E-gel<sup>®</sup>, which are semi-solid enteral nutrients marketed in Japan.

17

18

19    **MATERIALS AND METHODS**

20    **Chemicals**

21       CBZ was purchased from Wako Pure Chemical Ind. (Osaka, Japan). Liquid and  
22   semi-solid RACOL<sup>®</sup> and HINE E-gel<sup>®</sup> were obtained from Otsuka Pharmaceutical Co.,

1 Ltd. (Tokyo, Japan). All other reagents were of commercial or analytical grade,  
2 requiring no further purification.

3

#### 4 **Animal care and treatment**

5 Male Sprague-Dawley rats, aged 7 weeks, were obtained from Japan SLC, Inc.  
6 (Hamamatsu, Japan). Rats were acclimatized for at least 2 days before being assigned  
7 to their experimental groups, and were housed in a clean room maintained at  $23 \pm 2^{\circ}\text{C}$   
8 with a relative humidity of  $55 \pm 10\%$  and 12-h light/dark cycle. They were allowed  
9 free access to a regular animal diet and tap water. The left jugular vein of rats was  
10 cannulated with polyethylene tubing (Natsume Seisakusyo Co., Ltd., Tokyo, Japan)  
11 under anesthesia, and the tube was then externalized to the interscapular area. Rats  
12 were fasted overnight following surgery. CBZ was orally administered at a dosage of  
13 75 mg/kg and volume of 2.5 mL/kg. Each semi-solid enteral nutrient at a dosage of  
14 2.5 kcal/kg was orally administered to rats immediately after CBZ dosing. Liquid and  
15 semi-solid formulations are both marketed in Japan for RACOL<sup>®</sup>, and thus liquid  
16 RACOL<sup>®</sup> (2.5 kcal/kg) was orally administered to control rats under the same  
17 conditions as the semi-solid preparations. Serial blood samples were obtained from  
18 the left jugular vein 2, 5, 15, and 30 min, and 1, 2, 3, and 5 hr after the oral  
19 administration of CBZ and were replaced with an equal volume of saline. In order to  
20 maintain patency, a small volume of heparinized saline was used to fill the cannula after  
21 the collection of each blood sample. Heparinized saline was removed just before the  
22 collection of the next blood sample. Collected blood was centrifuged at 3,000 g for 10

1 min to obtain serum samples. The experimental protocols and animal care methods  
2 used in the present study were approved by the Animal Experiment Committee at Osaka  
3 Ohtani University.

#### 4 5 **Measurement of serum CBZ concentrations**

6 Fifty microliters of 50 µg/mL phenacetin, an internal standard, 50 µL of 0.1 M  
7 sodium hydroxide, and 750 µL of ethyl acetate were added to a 100-µL serum sample.  
8 The mixture was then vortexed and centrifuged at 5,000 g for 5 min. The organic layer  
9 was decanted into new tubes and evaporated using a centrifugal concentrator for dryness.  
10 The residues were resolved in 200 µL of the mobile phase and 50 µL was injected into  
11 the HPLC system (Shimadzu, Kyoto, Japan). The mobile phase consisted of 15 mM  
12 potassium phosphate buffer (pH 4.0) and acetonitrile (v/v: 66:34), and the flow rate was  
13 set at 1.0 mL/min. Absorbance of the eluent was monitored at 220 nm. The value of  
14 the area under the curve ( $AUC_{0\rightarrow 5h}$ ) was calculated by the linear trapezoidal method.

15

#### 16 **Statistical analysis**

17 Data were expressed as means  $\pm$  S.D. Comparisons among groups were made  
18 using an analysis of variance (ANOVA) followed by Tukey's test. Differences with a  
19 *p*-value of 0.05 or less were considered to be significant.

20

21

22

1   **RESULTS**

2   **Pharmacokinetics of CBZ after its oral administration**

3       The serum concentration-time profile of orally administered CBZ is shown in Figure  
4   1. The serum concentration of CBZ at each sampling point was lower in the  
5   semi-solid RACOL<sup>®</sup>-treated group than in the liquid RACOL<sup>®</sup>-treated group. No  
6   significant differences were observed in the serum concentration of CBZ at each  
7   sampling point between the semi-solid RACOL<sup>®</sup>-treated and HINE E-gel<sup>®</sup>-treated  
8   groups. The values of AUC<sub>0→5h</sub> were estimated using the linear trapezoidal method  
9   (Fig. 2). The value of AUC was significantly lower in the semi-solid RACOL<sup>®</sup>- and  
10  HINE E-gel<sup>®</sup>-treated groups than in the liquid RACOL<sup>®</sup>-treated group.

11

12                                   <Figs. 1 and 2>

13

14

15   **DISCUSSION**

16       Appropriate nutrition management plays an essential role in improving clinical  
17   outcomes. The semi-solidification of enteral nutrients is available as a strategy to  
18   prevent the complications associated with liquid enteral nutrients. However, limited  
19   information is currently available on the adverse effects of semi-solid enteral nutrients.  
20   In the present study, we investigated whether the pharmacokinetic behavior of CBZ was  
21   altered in rats treated with semi-solid enteral nutrients. To the best of our knowledge,  
22   this is the first study to provide experimental evidence for a possible interaction

1 between CBZ and semi-solid enteral nutrients.

2 The serum concentration of CBZ at each sampling point was lower in rats treated  
3 with semi-solid RACOL<sup>®</sup> at a dosage of 2.5 kcal/kg than in those treated with liquid  
4 RACOL<sup>®</sup> (2.5 kcal/kg), resulting in a decrease in the AUC value. The bioavailability  
5 of CBZ was previously reported to be primarily influenced by the extent of absorption  
6 [9]. Although absolute bioavailability was not examined in the present study, relative  
7 bioavailability was estimated by comparing AUC values. Guar gum, xanthan gum,  
8 and sodium alginate, which are water-soluble fibers, are components of semi-solid  
9 RACOL<sup>®</sup> that semi-solidify the formulation. We previously reported that CBZ was  
10 adsorbed by guar gum and xanthan gum in solution, which reflected gastric juice and  
11 fluid in the intestinal tract, and this may be responsible for the alterations observed in  
12 the pharmacokinetic profile of CBZ [7]. Our previous findings also demonstrated the  
13 adsorption of CBZ onto sodium alginate in solution, which reflected fluid in the  
14 intestinal tract, resulting in reductions in the serum levels of CBZ following its oral  
15 administration [8]. Furthermore, SA was found to gel in the stomach when ingested  
16 [10]. Gelled SA was considered to have interacted with CBZ and affected the  
17 dissolution process of CBZ. Therefore, we suggest that the pharmacokinetic behavior  
18 of orally administered CBZ differed when administered concurrently with liquid  
19 RACOL<sup>®</sup> and semi-solid RACOL<sup>®</sup>, and also that the serum concentration of CBZ was  
20 reduced by the semi-solidification of enteral nutrients through the absorption process.  
21 Serum concentrations of CBZ at each sampling point after its oral administration to rats  
22 treated with HINE E-gel<sup>®</sup> were similar to those obtained in rats treated with semi-solid

1 RACOL<sup>®</sup>, which was reflected in the value of AUC. Pectin and calcium ions are  
2 components of HINE E-gel<sup>®</sup>. Divalent metal ions, such as calcium ions, crosslink  
3 between free carboxyl groups in pectin molecules to form a network structure, which  
4 results in the gelation of pectin. Gelled pectin was considered to have interacted with  
5 CBZ and affected the dissolution process of the drug. Therefore, we suggest that the  
6 pharmacokinetic behavior of CBZ was affected by a simultaneous treatment with HINE  
7 E-gel<sup>®</sup> similar to that with semi-solid RACOL<sup>®</sup>.

8 There is currently no clinical evidence for a pharmacokinetic interaction between  
9 CBZ and semi-solid enteral nutrients. However, the proposed daily requirement of  
10 nutrition for Japanese adults is approximately 20-25 kcal/kg to maintain the basal  
11 metabolic rate, which is markedly higher than the dose adopted in the present study (2.5  
12 kcal/kg). Thus, the pharmacokinetic behavior of CBZ may be altered by a treatment  
13 with semi-solid enteral nutrients in clinical practice, necessitating healthcare personnel  
14 to pay careful attention to unexpected therapeutic failures. **The pharmacokinetics of  
15 CBZ in regular diet may be close to that in semi-solid enteral formula, since the diet  
16 contains abundant dietary fiber. However, the fibers contained in the regular diet and  
17 the enteral nutrient are different, and the fibers contained in the latter have the property  
18 of strongly adsorbing to the drug. Therefore, it was thought that patients taking these  
19 semi-solid enteral nutrients had lower blood levels of CBZ than patients taking their diet,  
20 which in turn reduced the therapeutic efficacy of CBZ.** On the other hand, individual  
21 differences may exist in the alterations that occur in serum levels of CBZ by treatments  
22 with semi-solid enteral nutrients because the dissolution rate of CBZ in gastrointestinal



1 fluid was found to be slow and the drugs possessed anticholinergic properties (Chen et  
2 al., 2002). Furthermore, tablets and capsules are widely used in clinical practice,  
3 although some patients are administered by the simple suspension method, and thus  
4 their disintegration and dissolution are extremely important factors when evaluating  
5 pharmacokinetic interactions. In this regard, further clinical examinations on the  
6 interaction between CBZ and semi-solid enteral nutrients are needed in the near future.

7 In conclusion, we herein demonstrated using rats that a pharmacokinetic interaction  
8 may occur between CBZ and semi-solid enteral nutrients, such as semi-solid RACOL®  
9 and HINE E-gel®. Our results will contribute to promoting appropriate nutritional  
10 management in pharmacotherapy.

11

12

### 13 REFERENCES

- 14 1. Reignier J, Darmon M, Sonnevile R, Borel AL, Garrouste-Orgeas M, Ruckly S  
15 Souweine B, Dumenil AS, Haouache H, Adrie C, Argaud L, Soufir L, Marcotte G,  
16 Laurent V, Goldgran-Toledano D, Clec'h C, Schwebel C, Azoulay E, Timsit JF,  
17 OutcomeRea Network. Impact of early nutrition and feeding route on outcomes of  
18 mechanically ventilated patients with shock: a post hoc marginal structural model  
19 study. Intensive Care Med. 2015; 41: 875-886.
- 20 2. Finocchiaro C, Galletti R, Rovera G, Ferrari A, Todros L, Vuolo A, Balzola F.  
21 Percutaneous endoscopic gastrostomy: a long-term follow-up. Nutrition. 1997; 13:  
22 520-523.

- 1 3. Whelan K, Schneider SM. Mechanisms, prevention, and management of diarrhea in  
2 enteral nutrition. *Curr Opin Gastroenterol*. 2011; 27: 152-159.
- 3 4. Kanie J, Suzuki Y, Akatsu H, Kuzuya M, Iguchi A. Prevention of late complications  
4 by half-solid enteral nutrients in percutaneous endoscopic gastrostomy tube feeding.  
5 *Gerontology*. 2004; 50: 417-419.
- 6 5. Tanishima Y, Fujita T, Suzuki Y, Kawasaki N, Nakayoshi T, Tsuiboi K, Omura N,  
7 Kashiwaki N, Yanaga K. Effects of half-solid nutrients on gastroesophageal reflux in  
8 beagle dogs with or without cardioplasty and intrathoracic cardiopexy. *J Surg Res*.  
9 2010; 161: 272-277.
- 10 6. Watanabe S, Suemura K, Inoue N, Imai K, Aimoto T, Araki H. Pharmacokinetic and  
11 pharmacodynamic studies of drug interaction following oral administration of  
12 imipramine and sodium alginate in rats. *Naunyn-Schmiedeberg's Arch Pharmacol*.  
13 2008; 378: 85-91.
- 14 7. Nagai K, Omotani S, Otani M, Sasatani M, Takashima T, Hatsuda Y, Mukai J,  
15 Myotoku M. *In vitro* and *in vivo* effects of selected fibers on the pharmacokinetics  
16 of orally administered carbamazepine: Possible interaction between therapeutic  
17 drugs and semisolid enteral nutrients. *Nutrition*. 2018; 46: 44-47.
- 18 8. Nagai K, Omotani S, Ito A, Nishimura I, Hatsuda Y, Mukai J, Teramachi H,  
19 Myotoku M. Alterations in pharmacokinetics of orally administered carbamazepine  
20 in rats treated with sodium alginate: Possible interaction between therapeutic drugs  
21 and semi-solid enteral nutrients. *Drug Res (stuttg)*. 2018, in press.
- 22 9. Chen LC, Chen YF, Chou MF, Lin MF, Yang LL, Yen KY. Pharmacokinetic

1 interactions between carbamazepine and the traditional Chinese medicine Paeoniae  
2 Radix Biol Pharm Bull. 2002; 25: 532-535.

3 10. Kristensen M, Jensen MG. Dietary fibres in the regulation of appetite and food  
4 intake. Importance of viscosity. Appetite. 2011; 56: 65-70.

5

6

7 Figure captions

8 Figure 1. Serum concentration-time courses of CBZ after its oral administration to rats.

9 Serum concentrations of CBZ were measured after its oral administration (75 mg/kg).

10 Results are shown as the means  $\pm$  SD of **four rats per group**. Open circle: the liquid

11 RACOL<sup>®</sup> group; Closed circle: the semi-solid RACOL<sup>®</sup> group; Closed triangle: the

12 HINE E-gel<sup>®</sup> group.

13

14 Figure 2. AUC<sub>0→5h</sub> values of CBZ after its oral administration. The values of

15 AUC<sub>0→5h</sub> were calculated by the linear trapezoidal method. Results are shown as the

16 means  $\pm$  SD of **four samples per group**. \*: Significantly different from the mean value

17 of the liquid RACOL<sup>®</sup> group.

Fig. 1  
Nagai et al.




Fig. 2  
Nagai et al.

